ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,111Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 231

$501K Total Retail Price of All Prescriptions

Rank: 27 out of 231

293 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Delaware
Lower avg

Schedule Two
Controlled Substances

21% of this provider’s 293 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

10% of this provider’s 293 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 8,568 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $74 among peers.

Prescriptions per Patient

35 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Delaware
SIMVASTATIN 443 367 1 2
WARFARIN SODIUM 404 302 2 17
AMLODIPINE BESYLATE 331 302 3 4
INSULIN SYRINGE 327 214 4 43
METOPROLOL TARTRATE 314 278 5 12
FUROSEMIDE 282 232 6 6
OMEPRAZOLE 279 244 7 5
LISINOPRIL 248 201 8 1
MIRTAZAPINE 243 233 9 25
HYDROCHLOROTHIAZIDE 189 181 10 9
RISPERIDONE 186 155 11 34
TRAZODONE HCL 174 172 12 35
GLIPIZIDE 164 144 13 71
LANTUS 163 109 14 42
SYNTHROID 160 160 15 28
CITALOPRAM HBR 156 111 16 20
QUETIAPINE FUMARATE 152 150 17 39
LEVOTHYROXINE SODIUM 143 118 18 3
DONEPEZIL HCL 138 135 19 26
GABAPENTIN 137 97 20 15
NOVOLOG 135 93 21 72
ISOSORBIDE MONONITRATE ER 121 92 22 56
TAMSULOSIN HCL 118 115 23 30
DIVALPROEX SODIUM 114 109 24 53
HYDROCODONE-ACETAMINOPHEN 104 89 S3 25 21
METFORMIN HCL 99 90 26 7
ADVAIR DISKUS 92 88 27 50
FENTANYL 89 85 S2 28 69
POTASSIUM CHLORIDE 89 51 28 33
SERTRALINE HCL 84 67 30 18
LACTULOSE 84 77 30 84
NYSTATIN 81 79 32 87
DIOVAN 79 60 33 27
TRAMADOL HCL 77 71 34 16
AZITHROMYCIN 71 56 35 32
AMLODIPINE BESYLATE-BENAZEPRIL 70 70 36 94
LEVETIRACETAM 68 67 37 57
CARVEDILOL 68 44 37 24
CYMBALTA 68 68 37 46
CLONIDINE HCL 66 66 40 63
LEVOFLOXACIN 64 62 41 64
CIPROFLOXACIN HCL 60 57 42 58
SPS 59 54 43 211
JANUVIA 59 31 43 93
OXYCODONE HCL 58 44 S2 45 23
METOPROLOL SUCCINATE 56 56 46 13
CLONIDINE 56 54 46 171
SEROQUEL 55 52 48 83
RANITIDINE HCL 55 34 48 51
CLOPIDOGREL 54 40 50 44
AMOX TR-POTASSIUM CLAVULANATE 52 50 51 81
ATORVASTATIN CALCIUM 50 42 52 8
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 26, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.